All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

CDKN2C Recombinant Monoclonal Antibody

Datasheet
Code CSB-RA580611A0HU
Size US$210
Order now
Image
  • Overlay Peak curve showing jurkat cells stained with CSB-RA580611A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*106cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/1*106cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
P42773
Target Names
CDKN2C
Alternative Names
Cyclin-dependent kinase 4 inhibitor C (Cyclin-dependent kinase 6 inhibitor) (p18-INK4c) (p18-INK6), CDKN2C, CDKN6
Species Reactivity
Human
Immunogen
A synthesized peptide from human CDKN2C protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
Rabbit IgG
Clone No.
2D11
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
Form
Liquid
Tested Applications
ELISA, FC
Recommended Dilution
Application Recommended Dilution
FC 1:50-1:200
Protocols
ELISA Protocol
Flow Cytometry (FC) Protocol
Troubleshooting and FAQs
Antibody FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

CDKN2C, also known as p18-INK4c, functions as a critical regulator of cell cycle progression by specifically inhibiting cyclin-dependent kinases 4 and 6. This tumor suppressor protein plays an essential role in controlling the G1-to-S phase transition, making it a significant target for researchers investigating cell cycle dysregulation, cancer biology, and cellular senescence mechanisms. Understanding CDKN2C expression patterns and function provides valuable insights into how cells maintain proliferative control and how this control becomes compromised in malignancy.

This recombinant monoclonal antibody, generated against a synthesized peptide derived from human CDKN2C, offers the reproducibility and consistency that demanding experimental workflows require. As a sequence-defined reagent produced through recombinant technology, it eliminates the lot-to-lot variability that can complicate longitudinal studies or multi-site collaborations. The rabbit IgG format, purified by affinity chromatography, ensures high specificity for your target while minimizing background interference.

Validation studies confirm reliable performance in flow cytometry applications, with recommended dilutions ranging from 1:50 to 1:200. Testing in Jurkat cells, a human T lymphocyte line commonly used in cell cycle and apoptosis research, demonstrated clear positive signal separation from isotype control when cells were fixed and permeabilized, indicating effective detection of intracellular CDKN2C. The antibody has also been validated for ELISA, providing flexibility across different experimental platforms.

This antibody serves researchers exploring CDK inhibitor biology, tumor suppressor mechanisms, hematopoietic cell differentiation, and therapeutic strategies targeting cell cycle regulators. Its validated performance in human samples makes it particularly suitable for oncology research and studies examining proliferative disorders.

Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

CDKN2C Antibodies

CDKN2C Proteins

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB.
Gene References into Functions
  1. Low P18 expression is associated with multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors. PMID: 29134609
  2. Cycling hypoxia could induce significant changes in CLDN1 and CLDN7 expression in nasopharyngeal cancer cells, indirectly regulation P18 expression and affecting cell invasion/proliferation. PMID: 28055967
  3. genetic association studies in population in Houston TX: Data suggest that CDKN2C copy number variations are associated with sporadic medullary thyroid carcinoma; these associations include presence of distant metastasis at presentation and decreased overall survival. PMID: 27610696
  4. CDKN2C gene deletion is associated with plasma cell post-transplantation lymphoproliferative disorders. PMID: 27750397
  5. Our study suggests that p18 is a limiting factor for the noncanonical HSC differentiation path in lymphoid lineages. PMID: 27287689
  6. CDKN2C inactivation contributes to the leukemogenesis in acute promyelocytic leukemia. PMID: 27888400
  7. DNA methyltransferase 3A promotes cell proliferation by silencing CDK inhibitor p18INK4C in gastric carcinogenesis PMID: 26350239
  8. Data suggest that cell cycle-dependent kinase inhibitors CDKN2C/p18 and CDKN1A/p21 facilitate cell cycle entry/cell proliferation of quiescent adult human pancreatic beta cells in primary culture (from tissues obtained from organ donors). PMID: 26740620
  9. Mutations in CDKN2C is associated with sporadic parathyroid adenoma. PMID: 24127162
  10. Analysis of B1a lymphocyte phenotypes of p18-deficient C57BL/6 mice finds that p18 is a key regulator of the size of the B1a cell pool. PMID: 22896639
  11. up-regulated HULC promotes proliferation of hepatoma cells through suppressing p18 PMID: 22685290
  12. Data indicate that the role of CDKN2C in the adverse outcome of cases with hemizygous deletion was less certain. PMID: 21994415
  13. results demonstrate for the first time that N-Myc is a downstream target of RET2A signaling, and propose that induction of N-Myc by RET2A is a key step leading to lower p18 levels during MEN2A tumorigenesis PMID: 21112821
  14. conclude that E2F proteins and Sp1 play an important role in the control of p18 expression PMID: 12077144
  15. Deletions in the CDKN2C locus and hypermethylation in the CDKN2C promoter region play a role in ovarian granulosa cell tumorogenesis. PMID: 12203782
  16. p18INK4c may function as a tumor suppressor in Hodgkin lymphoma, and inactivation may contribute to cell cycle deregulation and defective terminal differentiation of the Reed-Sternberg cells. PMID: 14645011
  17. protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c) PMID: 15107819
  18. p18(INK4C) loss may contribute to medulloblastoma formation in children PMID: 16260494
  19. oncogenic RET and loss of p18 cooperate in the multistep tumorigenesis of medullary thyroid carcinoma PMID: 18316595
  20. NaBu-mediated p18( INK4C ) regulation played a role in cell cycle arrest and erythroid differentiation in K562 cells. PMID: 18642058
  21. deletions of CDKN2C are important in the progression and clinical outcome of myeloma PMID: 18829482
  22. P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma PMID: 18942719
  23. Purpose was to investigate genetic alterations of CDKN2C gene in 38 pituitary adenomas. The absence of CDKN2C protein was correlated with LOH of the CDKN2C locus on chromosome 1 and with methylation of the CDKN2C promoter. PMID: 18973139
  24. The down-regulation of p18(INK4C) expression may contribute to the tumorigenesis of pituitary adenomas. PMID: 19401813
  25. p18(INK4C) is a downstream target of GATA3, constrains luminal progenitor cell expansion, and suppresses luminal tumorigenesis in the mammary gland PMID: 19411068
  26. Results identified a molecular basis for CDK inhibitors to exert an antitumor effect in p18-deficient cancers and support the clinical use of CDK inhibitors. PMID: 19509251

Show More

Hide All

Protein Families
CDKN2 cyclin-dependent kinase inhibitor family
Tissue Specificity
Highest levels found in skeletal muscle. Also found in pancreas and heart.
Database Links

HGNC: 1789

OMIM: 603369

KEGG: hsa:1031

STRING: 9606.ENSP00000262662

UniGene: Hs.525324

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

Related Articles
Antibody FAQs What Is an Antibody? How to Choose an Antibody for Scientific Research? The difference between primary antibody and secondary antibod The Meaning of Irregular Antibody Screening Tag Antibodies, Your Good Partner in Protein Research How to Choose the Loading Control Antibodies?
Related pathways
Cell cycle
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
No. 269, Shendun 5th Road, Donghu Hi-Tech Development Area, Hubei Province, 430206, P.R.China
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*